Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 3/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | IGF2BP1 | Q9NZI8 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | STAT3 | P40763 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cucurbitacin E SCHEMBL10013363 | 1.00 | ITGAL (0.83) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin E SCHEMBL20121528 | 1.00 | ITGAL (0.83) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin E SCHEMBL22878009 | 1.00 | ITGAL (0.83) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin E SCHEMBL27783763 | 1.00 | ITGAL (0.83) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin E SCHEMBL29908892 | 0.93 | ITGAL (0.84) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin I SCHEMBL23999338 | 0.91 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin I SCHEMBL15914446 | 0.91 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin I SCHEMBL10013366 | 0.91 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin I SCHEMBL23219974 | 0.91 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 | |
| Cucurbitacin I SCHEMBL22791196 | 0.91 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1APAX8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| WO-2025073376-A1 | MASKING PREPARATIONS AND COMPOUNDS FROM DAEMONOROPS DRACO (DRAGON BLOOD) | SYMRISE AG (DE) | 2025-04-10 | — | — | WO | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| CN-119677779-A | Combination therapy with anti-nucleolin 1 antibodies and antibody conjugates | 儿童医学中心公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4514857-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4514858-A2 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| CN-119487077-A | Mutant and mislocalized cell surface nucleolin 1 as diagnostic and therapeutic targets for human diseases | 儿童医学中心公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-118403163-A | Medical application and pharmaceutical composition of PIN1/CDK1-pVHL signal path interfering agent | 暨南大学 | 2024-07-30 | — | — | CN | claimed |
| WO-2006133461-A1 | IDENTIFICATION OF TERPENOID-BIOSYNTHESIS RELATED REGULATORY PROTEIN-REGULATORY REGION ASSOCIATIONS | CERES INC. (US) | 2006-12-14 | — | — | WO | claimed |
| US-20060246161-A1 | METHOD OF MAKING MEDICAMENT FOR TREATING ANEMIA | ULTRA BIOTECH LIMITED (GB) | 2006-11-02 | — | — | US | claimed |
| WO-2006113481-A1 | SECONDARY METABOLITE PRODUCTION VIA MANIPULATION OF GENOME METHYLATION | CERES INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20060236421-A1 | Secondary metabolite production via manipulation of genome methylation | CERES, INC. | 2006-10-19 | — | — | US | claimed |
| US-20040138189-A1 | Moderation of intracellular signals; antitumor agents; drug screening; administering cucurbitacin compound | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-15 | — | — | US | claimed |
| EP-1408749-A4 | CUCURBITACIN-CONTAINING INSECTICIDAL COMPOSITIONS | US AGRICULTURE (US) | 2004-05-19 | — | — | EP | claimed |
| EP-1408749-A2 | CUCURBITACIN-CONTAINING INSECTICIDAL COMPOSITIONS | THE UNITED STATES OF AMERICA as represented by THE SECRETARY, UNITED STATES DEPARTMENT OF AGRICULTURE (US) | 2004-04-21 | — | — | EP | claimed |
| WO-2002078617-A2 | MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002058463-A2 | CUCURBITACIN-CONTAINING INSECTICIDAL COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2002-08-01 | — | — | WO | claimed |
| US-5925356-A | Method of isolating cucurbitacin | JP MORGAN CHASE BANK | 1999-07-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246161-A1 | METHOD OF MAKING MEDICAMENT FOR TREATING ANEMIA | HBG1, HBG2, HBZ | ITGAL 1266/4885SMN1; SMN2 2007/4885HIF1A 69/4885 |
| US-20040138189-A1 | Moderation of intracellular signals; antitumor agents; drug screening; administering cucurbitacin compound | STAT3, STAT1, JAK2 | ITGAL 4681/4885SMN1; SMN2 4227/4885HIF1A 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.